Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA

Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers

Salesforce and Azim Premji Foundation launch VaxIT app to speed up Covid-19 vaccination

The VaxIT app, developed on the Salesforce platform for Azim Premji Foundation and its partners, captures the status of vaccinations to help individuals plan and stay updated on their progress

Merck’s tepmetko receives positive CHMP opinion in Europe

The medicine is the first and only oral MET inhibitor to receive CHMP positive opinion in Europe for adult patients with advanced NSCLC harbouring alterations leading to METex14 skipping

New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination

Effectiveness of Covaxin against the Omicron variant is currently being studied

U.S. FDA approves Bristol Myers Squibb’s Orencia

Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant

Six benefits of Cloud Computing in the pharma industry

Immatics and Bristol Myers Squibb enter exclusive license for TCR Bispecific programme

Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales

Pfizer to acquire Arena Pharmaceuticals for US $ 6.7 bn

The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases

Lupin’s Goa plant receives EIR from US FDA

FDA changes inspection classification of the facility to Voluntary Action Indicated

Trastuzumab Deruxtecan supplemental New Drug Application for breast cancer submitted in Japan

In Japan, breast cancer is the most common cancer in women, with approximately 92,000 cases of breast cancer diagnosed in 2020